Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha 1 antitrypsin - CSL Behring

Next Previous
Drug Profile

Alpha 1 antitrypsin - CSL Behring

Alternative Names: AAT - CSL Behring; Alpha-1 proteinase inhibitor - CSL Behring; Alpha-antitrypsin - CSL Behring; API; API Inhale; CSL 964; Respreeza; Zemaira

Latest Information Update: 04 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer Blood and Marrow Transplant Clinical Trials Network; CSL Behring; Nektar Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase III Graft-versus-host disease

Most Recent Events

  • 02 Jan 2024 Preregistration for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
  • 02 Jan 2024 Registered for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
  • 17 Nov 2021 Phase-III clinical trials in Graft-versus-host disease (In adolescents, Prevention, In adults) in Spain, USA, Australia, United Kingdom, Italy, Germany (IV) before November 2021 (CSL Behring pipeline, November 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top